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A B S T R A C T
Purpose: This study developed a comprehensive measurement tool for assessing dyspnea in cancer patients and
examined its reliability and validity.
Methods: This cross-sectional study included 239 cancer patients with awareness of cancer-related dyspnea from
outpatient/inpatient wards of six general hospitals in Japan. Items for the Total Dyspnea Scale for Cancer
Patients (TDSC) were developed based on qualitative research and a literature review on patients with dyspnea.
Ten cancer experts conﬁrmed the scale's content validity. Factor analysis established construct validity. Internal
consistency was analyzed by Cronbach's α. Study variables were the eﬀects of dyspnea, worry, and quality of life.
Results: Factor analysis identiﬁed 2 factors (11 items): eﬀects on “daily living activities and psychology” and on
“social life.” Cronbach's α of the whole scale was 0.952 (p < 0.01), conﬁrming high reliability. The scale
showed high correlation with existing measures. TDSC can comprehensively and multidimensionally evaluate
cancer-related dyspnea.
Conclusions: The TDSC consists of 11 items within two factors. Cronbach's α coeﬃcient of the scale was 0.952 in
this study, and thus, an acceptable level of reliability was conﬁrmed. In addition, reference-related validity and
discriminant validity were veriﬁed and conﬁrmed. In future clinical practice, this scale can be utilized as a useful
tool for comprehensively and multidimensionally evaluating cancer-related dyspnea.
1. Introduction
Dyspnea is a common symptom in cancer patients. The frequency of
occurrence of respiratory distress symptoms in cancer patients varies
from 29% to 74% (Ahmedzai, 1998) according to the literature, but it is
particularly frequent in the advanced and terminal stages of cancer.
Furthermore, due to worldwide population growth and population
aging, it is expected that the number of cancer patients will increase to
22 million in 2032, 1.5 times more than in 2012 (World Health
Organization, 2014). Therefore, the improvement of support services
for cancer patients and survivors worldwide is necessary, and it is also
essential to develop nursing care to manage symptoms such as dyspnea.
Dyspnea is related to not only physical deterioration but also an-
xiety and depression (Tanaka et al., 2002). Onset due to psychological
eﬀects such as anxiety is particularly speciﬁc to cancer patients and
must be emphasized. A previous study revealed that the experience of
dyspnea in patients during treatment of lung cancer is inﬂuenced by
various aspects: physical, psychological, social, and existential
(Hashimoto and Kanda, 2011). This suggests that comprehensive sup-
port from the perspective of “total dyspnea” is essential to deal with this
symptom. However, treatment and care for patients with dyspnea has
not yet been established and remains in development. Systemic ad-
ministration of morphine is noted as eﬀective in alleviating dyspnea in
the Guidelines for Relieving Respiratory Symptoms in Cancer Patients
(Ben-Aharon et al., 2012). It is recommended that its usage be started
soon after the onset of symptoms and be increased according to the
condition (Japan Medical Association, 2008), but the present reality is
that morphine use for dyspnea is not suﬃciently widespread in the
palliative care setting (Ochi et al., 2013).
Meanwhile, as alternatives to pharmacotherapy, ventilation (Wong
et al., 2017), and relaxation (Corner et al., 1996) in recent years have
been found to relieve dyspnea and contribute to maintenance or im-
provement in quality of life (QOL). These methods are expected to
become more widespread and popularized in the future, but they have
not yet fully inﬁltrated the clinical setting. It is thus diﬃcult to alleviate
cancer-related dyspnea, and in the terminal stage, there is no other
choice but to begin morphine administration to relieve the pain. This
situation reduces cancer patients’ QOL and is an urgent global problem
that must be solved. It is necessary to develop an assessment tool that is
quick and does not distress patients in order to identify care needs that
are not evident on the surface.
Several scales assessing cancer-related dyspnea already exist: the
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Cancer Dyspnea Scale (CDS) (Tanaka et al., 2000), the Support Team
Assessment Schedule (STAS) (Carson et al., 2000), the M. D. Anderson
Symptom Inventory (MDASI) (Cleeland et al., 2000), and the European
Organization for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ) (Kobayashi et al., 1998). Additionally,
although there is a scale developed for COPD patients, the Short Form
Chronic Respiratory Questionnaire (SF-CRQ; Charalambous & Mo-
lassiotis, 2017), its reliability and validity for lung cancer patients has
been veriﬁed through randomized controlled trial. There is a scale that
can be veriﬁed and considered for use.
The CDS was developed speciﬁcally for cancer patients. Its relia-
bility and validity have been conﬁrmed in Japan; however, it requires
complicated calculations to obtain scores. Further, it can only assess the
nature of dyspnea, and its practical use is limited to indicating the
necessity of treatment (Okuyama et al., 2001, 2003), making it diﬃcult
to use in clinical practice. The STAS can evaluate the extent to which
symptoms inﬂuence daily activities. However, it is only a proxy as-
sessment tool completed by medical staﬀ and does not necessarily re-
ﬂect the patient's subjective opinions. The MDASI and EORTC QLQ
include items assessing the extent of the inﬂuence of dyspnea on factors
such as daily activities and physical aspects and can be used to evaluate
the impact on QOL. However, they include many items and can cause
signiﬁcant stress in patients. Further, these scales determine the inﬂu-
ence of several symptoms in addition to dyspnea. Therefore, they are
limited in terms of obtaining information on dyspnea from a compre-
hensive perspective. In addition, although SF-CRQ can be used for
cancer patients, it has many items and takes time to complete, and so is
diﬃcult to use for subjects with impending respiratory distress symp-
toms. Further, it includes numerous items and takes time to complete
making it diﬃcult to use with subjects experiencing urgent dyspnea
symptoms. Currently, to measure total dyspnea, the only option is to
examine it from various dimensions by integrating multiple scales. A
suitable scale that considers patients' stress is non-existent. As such,
there is a pressing need to develop an assessment tool that can com-
prehensively evaluate dyspnea from various perspectives in a simpler
way.
The development of a simple assessment tool that decreases the
interaction time between medical personnel and patients will be ben-
eﬁcial for medical personnel as it can enable eﬀective intervention. If
details of the patient's distress can be understood immediately, a con-
crete course of action can be speciﬁed, promptly leading to the provi-
sion of speciﬁc care. Therefore, this study developed a scale to com-
prehensively measure dyspnea in cancer patients and examined the
scale's reliability and validity. This scale, which encompasses multiple
dimensions, is highly user-friendly and could be used in other countries
to deal with cancer-related dyspnea.
2. Purpose
This study developed a comprehensive assessment scale for mea-
suring cancer-related dyspnea and investigated its reliability and va-
lidity.
3. Method
3.1. Design
This study used a cross-sectional design to achieve its objectives.
3.2. Conceptual model
The present researchers created a developmental model for the
Total Dyspnea Scale for Cancer Patients (TDSC) based on the Revised
Model for Symptom Management (Revised MSM) by Dodd et al. (2001),
which was created by revising the model for symptom management
developed by Larson et al. (1994) (Fig. 1). This study theoretically
established that the eﬀects of cancer-related dyspnea can be organized
into three types: physical, social, and emotional/spiritual eﬀects. The
CDS was also used to measure dyspnea. Further, breathing diﬃculties
are a serious concern. Therefore, the Brief Cancer-Related Worry In-
ventory (BCWI) was used to measure cancer-related worry. In addition,
the experience of breathing diﬃculty aﬀects cancer patients’ QOL. QOL
was measured using the Functional Assessment of Cancer Therapy-
General (FACT-G) (Vol. 4).
3.3. Process of developing the original measurement scale
The ﬁrst step was to extract concepts and to create questionnaire
items. In order to clarify the concept of cancer-related dyspnea, concept
analysis was performed using Walker and Avant's concept analysis
method (Heyse-Moor et al., 2000; van der Molen, 1995). The results of
the concept analysis (Hashimoto et al., 2017) clarifying the attributes of
dyspnea in cancer patients showed that it inﬂuences several factors:
daily living activities, physical aspects, psychological aspects, social
aspects, and spirituality. These formed one element of the scale. In
addition, an existing scale related to the feeling of breathing was added.
The contents of these item pools were organized, and a draft ques-
tionnaire of 73 items was created.
Second, content validity was examined with the help of cancer ex-
perts. A questionnaire survey was administered to ten experts, in-
cluding specialized oncology nurses, cancer nursing researchers, and
cancer specialists. Based on the questionnaire responses, the coin-
cidence ratio of all items was calculated, and items with less than 70%
coincidence were deleted. The remaining 47 items were included in a
draft of the scale.
Third, a provisional scale was developed by modifying the draft
based on a pretest. From May to June 2017, a pretest was conducted
using the original scale. The subjects were 10 males and females with
lung, mammary gland, and prostate cancer. Based on their opinions,
items with similar content were integrated or expressions were mod-
iﬁed to develop a provisional scale of 45 items.
3.4. Present survey
3.4.1. Participants and setting
The subjects were cancer patients with awareness of dyspnea related
to cancer. The sample size was determined to be 225 using the power
analysis software G-power (Ver. 3.1). The investigation period was from
June 2017 to June 2018. The survey was conducted at outpatient and
inpatient wards of six general hospitals in Japan.
3.4.2. Methodologic approach and variables
Questionnaires were distributed to the subjects who agreed to par-
ticipate in the study. They were asked to return the completed ques-
tionnaire by mail or to place it in a collection box. In addition, basic
information about the subjects was collected by viewing the electronic
medical chart.
The questionnaire survey included the following: the newly devel-
oped scale (TDSC); existing scales (CDS [Tanaka et al., 2000], BCWI
[Hirai et al., 2008], FACT-G Version 4 [Cella et al., 1993]); and sup-
plemental questions about attributes. CDS is a dyspnea measure de-
veloped for cancer patients. It is a ﬁve-point Likert scale consisting of
12 items in 3 factors: sense of respiratory eﬀort (5 items); sense of
breathing discomfort (3 items); and sense of respiratory anxiety (4
items). The higher the score, the stronger the breathing diﬃculty
(Cronbach's α: 0.64). BCWI is a psychological measure to evaluate
cancer-related worry among cancer patients. It consists of 15 items in 3
factors: future prospects (6 items); physical and symptomatic problems
(4 items); and social and interpersonal problems (5 items). The higher
the score, the greater the worry (Cronbach's α: 0.87). FACT-G was de-
veloped to measure cancer-speciﬁc health-related QOL. It is a four-level
Likert scale consisting of 27 items in 4 factors: physical well-being (7
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items); functional well-being (7 items); psychological well-being (6
items); and social/family well-being (7 items). The higher the score, the
higher the QOL (Cronbach's α: 0.89).
The main study variables were the eﬀects of dyspnea, pain of dys-
pnea, concern, and quality of life.
3.5. Analysis method
Statistical analyses were conducted using IBM SPSS Statistics
Version 25.0, and the following procedures were carried out. After
determining the items to be deleted due to ceiling/ﬂoor eﬀects or inter-
item correlation analysis, item-total correlation (I-T correlation) was
performed with the revised items. Regarding construct validity, an ex-
ploratory factor analysis was performed based on the principal factor
method using ProMax rotation with the items remaining after item
analysis. Items with low communality or low factor loading were re-
moved. Each factor was named based on its interpretation.
Subsequently, a model was constructed for conﬁrmatory factor analysis,
and the goodness of ﬁt was conﬁrmed through covariance structure
analysis. The following goodness of ﬁt indices were employed: GFI
(goodness of ﬁt index), AGFI (adjusted goodness of ﬁt index), CFI
(comparative ﬁt index), and RMSEA (root mean square error of ap-
proximation). Internal consistency was conﬁrmed through calculations
of Cronbach's α coeﬃcients for the whole scale and for each factor.
Further, regarding stability, conﬁdence coeﬃcients were calculated and
investigated according to the split-half method using the Spearman-
Brown formula. Regarding criterion-related validity, correlation coef-
ﬁcients were calculated and investigated with the CDS, FACT-G, and
BCWI as external criteria. Further, for discriminant validity, for the CDS
and BCWI, the top 10% in total scores were classiﬁed as a high-score
group, while the bottom 10% were classiﬁed as a low-score group, and
the discriminatory power with the total scale score was evaluated by a
t-test.
3.6. Ethical considerations
This study was approved by the ethical review board for medical
research of Gunma University and the institutional review board of
each institution (2016-097). Information regarding the purpose and
content of the study, study methods, voluntary participation, right to
withdraw, protection of personal information, guarantee of anonymity,
data storage and deletion methods, and publication of research results
was provided to all subjects orally and through a written document.
They were told that they would suﬀer no disadvantage in treatment or
care for refusing to participate. Consent for participation was obtained
by signing an informed consent form. Existing scales were used after
obtaining permission from the original creators.
4. Results
Of the 278 individuals who agreed to participate, responses were
received from 260 individuals (response rate: 93.5%). Of these, 21 were
judged as invalid responses and excluded owing to incomplete data; for
example, missing responses to questions in the newly developed scale
or the existing scales or failing to answer at least 90% of other questions
such as subject characteristics. There were ultimately 239 valid re-
sponses which were used for analysis (valid response rate 91.9%).
4.1. Subjects’ characteristics
There were 135 males (56.5%) and 104 females (43.5%), with an
average age of 67.42 (± 11.33) years (see Table 1). The most common
cancer site was the gastrointestinal system (38.1%), followed by the
lungs (32.2%). Cancer in these two organ systems comprised over two-
thirds of all cases. Regarding cancer stage, 72.0% of the patients had
Fig. 1. Developmental model for the Total Dyspnea Scale for Cancer Patients.
Table 1
Subjects' characteristics (N= 239).
Characteristics n %
Gender Male 135 56.5
Female 104 43.5
Age Mean (± SD) 67.42
(± 11.33)
Median Range 6924–91
Performance Statistics 0 36 15.1
1 61 25.5
2 137 57.3
3 5 2.1
Cancer Site Gastrointestinal system 91 38.1
Lungs 77 32.2
Breasts 17 7.1
Blood/hematopoietic 16 6.7
Urinary system 9 3.8
Uterus/ovaries/vagina 9 3.8
Otolaryngeal/pharyngeal/
neck
4 1.7
Prostate gland 3 1.3
Other 13 5.4
Stage Stage I 5 2.1
Stage II 14 5.9
Stage III 31 13.0
Stage IV 172 72.0
Treatment Environment Unknown 17 7.1
Inpatient 118 49.4
Outpatient 121 50.6
Inhaled Oxygen Therapy Yes 95 39.7
No 144 60.3
Resting SpO2 ≥95% 217 90.8
90%–95% 21 8.8
≤90% 1 0.4
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Stage IV terminal cancer.
4.2. Item analysis
Of the 45 items, one item demonstrated a ceiling eﬀect, and no
items demonstrated a ﬂoor eﬀect. Pearson's product-moment correla-
tion coeﬃcients were calculated, and items demonstrating a strong
inter-item correlation (r > 0.70) were identiﬁed and investigated as
potential items to be deleted. When a strong correlation was observed
between several items, easier expressions or content specialized for
symptoms of dyspnea were prioritized, resulting in the removal of 30
items. There were no items demonstrating a weak correlation
(r < 0.30) to total score in I-T correlation analysis.
4.3. Exploratory factor analysis and factor naming
When factor analysis was performed with the 15 remaining items,
the Kaiser-Meyer-Olkin sampling adequacy value was 0.946, con-
ﬁrming satisfactory validity (see Table 2). The p-value for Bartlett's test
of sphericity was 0.000, conﬁrming inter-question correlation, and it
was determined that common factors should be investigated.
Next, when the exploratory factor analysis was performed through
the principal factor method with ProMax rotation, there was a large
slope of two to three in the scree plot, and the eigenvalue became
greater than one with two factors. The contribution rate of each factor
was in the range of 0.79%–7.32%, and the cumulative contribution
ratio was 64.1%. When factor analysis was repeated following the
standard of removing items with a factor loading of less than 0.4 and
those with a loading roughly equal to another factor, four items were
removed, and an eleven-item two-factor structure was adopted. This
was ﬁnally established as the TDSC.
The interpretation of each factor is as follows. Factor 1 was inter-
preted as items denoting diﬃculties or obstacles to daily living activ-
ities, such as eating, toileting, sleeping, and having conversations, oc-
curring due to dyspnea, as well as items denoting psychological
problems accompanying dyspnea in the form of worry, motivation, and
ease of breathing. This factor was named “eﬀects on daily living ac-
tivities and psychology.” Factor 2 was interpreted as items denoting
eﬀects on social roles in terms of one's job or activities in the commu-
nity, as well as eﬀects on participation in social activities of daily living
in the form of stress due to interacting with others—a necessary step in
engaging in social activities—and going up and down stairs—one daily
living activity necessary when going outdoors. This factor was named
“eﬀects on social activities.”
4.4. Conﬁrmatory factor analysis
To conﬁrm the factor structure, a conﬁrmatory factor analysis was
performed using the covariance structure analysis software IBM SPSS
Amos Version 25.0. The two factors and eleven items obtained from the
exploratory factor analysis were used provisionally to create a hy-
pothesis model assuming the covariance between factors. The goodness
of ﬁt indices did not meet the standard with values of GFI= 0.876,
AGFI= 0.842, CFI= 0.936, and RMSEA=0.108, but path coeﬃcients
were all above 0.4 (p < 0.01), conﬁrming an index that met acceptable
standards. However, because most subjects in the present survey had
been objectively judged to have dyspnea, the study sample was biased
in that there were more moderate cases than mild cases. This is assumed
to be the reason the model's goodness of ﬁt did not meet the standard.
4.5. Examination of reliability
Cronbach's α coeﬃcient for the whole scale was 0.952. Cronbach's α
for the factors was 0.947 for “eﬀects on daily living activities and
psychology” and 0.859 for “eﬀects on social activities.” As these ex-
ceeded the standard of 0.80 or above, internal consistency for the whole
scale and for each factor was conﬁrmed. When a conﬁdence coeﬃcient
was calculated using the Spearman-Brown formula according to the
split-half method, in which the ﬁnalized factors and items from factor 1
were arranged in order, numbered, and divided into even-numbered
and odd-numbered question groups, the conﬁdence coeﬃcient was
0.909 (p < 0.01), conﬁrming the scale's stability.
4.6. Examination of validity
4.6.1. Criterion-related validity
To investigate the relationship between the scale and external cri-
teria, correlations with the CDS, BCWI, and FACT-G were computed
(see Table 3). For the relationship with the CDS, a strong correlation
was conﬁrmed for the total score (r= 0.760, p < 0.01) and for factor 1
“eﬀects on daily living activities and psychology” (r= 0.779). For the
relationship with the BCWI, a moderate correlation was conﬁrmed for
the total score (r= 0.678, p < 0.01) and for factor 1 “eﬀects on daily
living activities and psychology” (r= 0.701, p < 0.01). For the
Table 2
Results of the factor analysis and item analysis for the Total Dyspnea Scale for Cancer Patients (N= 239).
Factor Item-total correlation co-eﬃcient
1 2
Factor 1: Eﬀects on daily living activities and psychology (α=0.947)
16: Labored breathing makes it diﬃcult to have a conversation 0.891 −0.011 0.865
2: Labored breathing makes it diﬃcult to swallow food and drink 0.876 −0.006 0.857
3: Due to labored breathing, I cannot bear down when having a bowel movement 0.818 0.033 0.887
17: Labored breathing makes it diﬃcult to sleep 0.796 0.115 0.840
1: I cannot breathe easily 0.723 0.104 0.818
34: Due to labored breathing, I do not have motivation to do anything 0.642 0.245 0.863
29: I always worry when it will become diﬃcult to breathe 0.478 0.393 0.844
Factor 2: Eﬀects on social activities (α= 0.859)
24: Due to labored breathing, I cannot participate in community gatherings or activities −0.038 0.896 0.795
21: Due to labored breathing, I cannot do my job as I would like to 0.008 0.732 0.713
25: Due to labored breathing, it is stressful to interact with those around me 0.294 0.590 0.839
12: Due to labored breathing, I cannot go up or down stairs 0.247 0.484 0.723
Inter-factor correlation (Factor 1) 1.000
(Factor 2) 0.797 1.000
The level for retaining an item was set at a factor loading higher than 0.4 (principal factor method with promax rotation), indicated in bold.
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relationship with the FACT-G, a moderate correlation was conﬁrmed for
the total TDSC score (r= 0.436, p < 0.01). The above relationships
with the CDS, BCWI, and FACT-G conﬁrmed criterion-related validity.
4.6.2. Discriminant validity
For the total scores of the CDS and BCWI, a high-score group
(n=24) and a low-score group (n=24) were created from the top
10% and bottom 10%, respectively, and a t-test was used to examine
signiﬁcant diﬀerences in the total scale score and sub-scale average
score. As a result, for all scales, the high-score and low-score groups
both demonstrated a p-value of 0.000, and a signiﬁcant diﬀerence in
average score was conﬁrmed (p < 0.05). This conﬁrmed discriminant
validity between the TDSC and the BCWI.
5. Discussion
5.1. Characteristics of Total Dyspnea Scale for Cancer Patients
This study developed a reliable and valid scale that can, for the ﬁrst
time, comprehensively evaluate breathing diﬃculty in cancer patients
worldwide. The TDSC has three features. First, it can comprehensively
assess dyspnea. The CDS, an existing scale, can only measure three
types of discomfort: respiratory eﬀort, respiratory discomfort, and re-
spiratory anxiety. The TDSC includes items related to behaviors easily
aﬀected by dyspnea, including eating, toileting, and engaging in con-
versations, as well as items related to social activities that are valued by
cancer patients. Thus, through this scale, it is possible to assess the
eﬀects of dyspnea in a multidimensional manner.
Second, the TDSC measures the feeling of dyspnea in cancer pa-
tients. This scale is based on patients' subjective evaluations, and its
foundation lies in qualitative research with cancer patients and concept
analysis. The item “I always worry when it will become diﬃcult to
breathe” was derived from the experience of dyspnea in cancer patients.
This shows that dyspnea is an experience accompanied by even greater
anxiety and fear, as it involves experiencing the fear of death because of
being unable to breathe as well as due to the worsening of cancer
(Hashimoto and Kanda, 2011). Because cancer patients are constantly
thinking about questions such as “Did my cancer become worse because
my symptoms have become worse?” and “Is death imminent?”
(Hashimoto and Kanda, 2011), they are always worried about when it
will become diﬃcult to breathe again. The fact that it includes such
items, which are characteristic of and important to cancer patients, is
an important feature of the TDSC. Further, although in theory the factor
structure was established according to three types of eﬀects—physical,
social, and emotional/spiritual—the results of the factor analysis in-
tegrated these types into the two factors of “eﬀects on daily living ac-
tivities and psychology” and “eﬀects on social activities.” Through the
analysis process, the dimension of physical and daily living activities
and the psychological dimension, denoting emotions, were integrated
into one factor. This is because it is diﬃcult to clearly separate the
physical and psychological dimensions, as dyspnea is perceived as not
only a physical sensation but also a psychological sensation. Further, as
Cronbach's α was similar for factors 1 (0.947) and 2 (0.859), both are
considered indispensable to patients. It was revealed that maintaining
both fundamental daily living activities and social activities is an
extremely important factor in maintaining QOL in cancer patients suf-
fering from dyspnea. Furthermore, the stairs rise and fall included in
the second factor is an item that can be positioned in activities of daily
living (ADL), which is the movement around the house at Barthel index
(Mahoney & Barthel, 1965)); however, in this study, the stairs rise and
fall is not was positioned as aﬀecting social life. This is considered to be
because the stairs that the subjects imagined were not the ones in the
house but the ones outside. In the outdoor environment on the go, there
are situations where you have to use the stairs, and because it is diﬃcult
to distribute the pace according to the symptoms due to the concern for
not giving trouble to the surroundings, it was interpreted by imaging
the stairs up and down outdoors. Interpretation of patients' subjective
thoughts and understanding was prioritized, and stair climbing was
positioned as the second factor. From this point as well, it is emphasized
that this scale reﬂects the patients' subjectivity.
Third, the TDSC excels in its simplicity. This scale has 11 items,
which is fewer than the CDS, and it can evaluate dyspnea from a
comprehensive perspective. Moreover, inverted items are not included;
this helps to maintain the simplicity of scoring. Furthermore, the items
of this scale are directly linked to the perspective of nursing interven-
tion by nurses. This measure consists of two subscales, which can clarify
the speciﬁc eﬀects of dyspnea. Therefore, it makes it easy to provide
directions for support, and it is also easy to evaluate. Because of this,
high utility can be expected in clinical practice.
5.2. Reliability and validity of the Total Dyspnea Scale for Cancer Patients
The scale's reliability has been established. Cronbach's α coeﬃcient
was 0.952, and the conﬁdence coeﬃcient from the split-half method
using the Spearman-Brown formula was 0.909, indicating acceptable
levels of internal consistency and stability. Further, regarding theory
construction for the TDSC, this was completed and the conceptual
model was created based on qualitative research with cancer patients
suﬀering from dyspnea (Hashimoto and Kanda, 2011) and concept
analysis using existing scales (Hashimoto et al., 2017), as well as
multiple other materials including previous research, related literature,
and the Revised MSM (Dodd et al., 2001). In the drafting stage, the
scale was determined to have consistency considering the response
concordance rate and the opinions of cancer experts regarding the
factors and questionnaire items. The internal consistency of the TDSC
was further veriﬁed because theory construction followed the above
process.
Regarding validity, the factor structure of the TDSC was found to be
valid based on Cronbach's α coeﬃcient for each factor as well as the
factor loading of each item. However, as most subjects in the present
survey had been objectively judged to have dyspnea, the study sample
was biased in that there were more moderate cases than mild ones. This
is assumed to be the reason the model's goodness of ﬁt did not meet the
standard. Accordingly, in the future, it will be necessary to conﬁrm the
model's goodness of ﬁt using a sample with a greater number of mild
cases and to re-examine the construct validity.
Regarding the exploration of criterion-related validity, signiﬁcant
positive correlations were observed between the TDSC, CDS, and BCWI.
As a strong correlation was seen in the TDSC's relationship with the
CDS, an existing scale, it is thought that the TDSC can successfully
Table 3
Correlations between the TDSC and the CDS, FACT-G, and BCWI (N=239).
CDS Total BCWI Total FACT-G Total
Correlation Coeﬃcient p Correlation Coeﬃcient p Correlation Coeﬃcient P
TDSC Total 0.760** 0.000 0.678** 0.000 0.436** 0.000
Eﬀects on daily living activities and psychology 0.779** 0.000 0.701** 0.000 0.399** 0.000
Eﬀects on social activities 0.664** 0.000 0.563** 0.000 0.436** 0.000
Pearson correlation coeﬃcient **p < 0.01.
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measure the same concept as an exterior criterion reﬂecting the concept
of cancer-related dyspnea. Additionally, in the relationship with the
external criterion of the BCWI, as a strong correlation was conﬁrmed
particularly for factor 1 “eﬀects on daily living activities and psy-
chology,” a correlation with worry was conﬁrmed. In other words, in-
dividuals who score high for dyspnea as measured by the TDSC also
score high for worry. A correlation was conﬁrmed with the TDSC be-
cause worry is a short-term response assessed simultaneously with
dyspnea. Meanwhile, in the relationship with FACT-G, moderate cor-
relations were conﬁrmed for the total score and factor 2. The reason a
strong correlation was not seen between the TDSC and QOL is probably
because QOL is a concept that cannot be recognized or assessed if there
is not some degree of long-term time lapse, and therefore, it is not as-
sessed simultaneously with dyspnea. Additionally, the results of a
comparison of the TDSC total score by a high group and a low group
with the BCWI total score demonstrated that the average BCWI score
was signiﬁcantly higher in the high group than the low group, con-
ﬁrming discriminant validity between the TDSC and BCWI.
5.3. Implications for nursing
The TDSC can be expected to be used as a clinical tool that can
comprehensively evaluate cancer-related dyspnea from a multi-
dimensional perspective. In addition, the use of the TDSC supports a
simple self-assessment of dyspnea, so that information is eﬀectively
provided to medical personnel. It can also be used for outcome as-
sessment in intervention studies aimed at alleviating dyspnea. The
TDSC may also help evaluate the eﬀectiveness of education to ease the
symptoms of dyspnea in cancer patients and assist them with coping
with the symptoms.
5.4. Limitations
Owing to the fact that the research subjects consisted of patients
with cancer, study subjects were primarily individuals with moderate
dyspnea, and the sample included only a small number of mild cases,
there is bias in the data. Therefore, it would be desirable to reverify the
scale's reliability and validity using a sample with an increased number
of mild cases.
6. Conclusion
The TDSC consists of 11 items in 2 factors. Cronbach's α coeﬃcient
of the scale was 0.952 in this study, and thus, an acceptable level of
reliability was conﬁrmed. In addition, reference-related validity and
discriminant validity were veriﬁed and conﬁrmed. In future clinical
practice, this scale can be utilized as a useful tool for comprehensively
and multidimensionally evaluating cancer-related dyspnea.
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